| Gonzalez, Maria Jesus |
ASPIRE, NCT04118088: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula |
|
|
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
NCT05357989: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
|
|
| Completed | 3 | 523 | Europe, US | buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo | Annovis Bio Inc., TFS Trial Form Support | Parkinson's Disease, Idiopathic | 12/23 | 12/23 | | |
| Recruiting | 2 | 70 | Europe | Ascorbic acid, Vitamin C, 0.9% Saline solution, Saline | Hospital Universitario Ramon y Cajal | Liver Transplantation, Postreperfusion Syndrome, Ascorbic Acid | 06/23 | 07/23 | | |
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults |
|
|
| Active, not recruiting | 2 | 797 | Canada, US, RoW | ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline | AEON Biopharma, Inc., PPD | Migraine | 06/24 | 09/24 | | |
NCT03340129: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) |
|
|
| Recruiting | 2 | 218 | Europe, RoW | Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy | Melanoma Institute Australia, Bristol-Myers Squibb | Melanoma Stage Iv | 08/24 | 08/25 | | |
| Recruiting | 2 | 68 | Europe | Adagrasib | ETOP IBCSG Partners Foundation, Mirati Therapeutics Inc. | NSCLC Stage IV, KRAS P.G12C | 10/25 | 03/26 | | |
STX-001-01, NCT06249048: Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab |
|
|
| Recruiting | 1/2 | 108 | US, RoW | STX-001, Keytruda®, Pembrolizumab | Strand Therapeutics Inc. | Advanced Solid Tumor | 05/27 | 11/28 | | |
NCT04232696: Neuspera's Implantable Sacral Nerve Stimulation System in Patients With Symptoms of Urinary Urgency Incontinence (UUI) |
|
|
| Active, not recruiting | N/A | 242 | Europe, US | Neuspera Implantable Sacral Nerve Stimulation System | Neuspera Medical, Inc. | Urinary Urgency Incontinence | 07/24 | 12/26 | | |
| Recruiting | N/A | 639 | Europe | | University Hospital, Strasbourg, France | COVID-19 | 12/23 | 12/23 | | |
| Recruiting | N/A | 80 | Europe, US | Oxygen | Boston Children's Hospital, Massachusetts General Hospital, Massachusetts Institute of Technology, National Institute for Biomedical Imaging and Bioengineering (NIBIB), Madrid-MIT M+Visión Consortium | Intrauterine Growth Restriction | 09/25 | 09/26 | | |
| Completed | N/A | 5694 | Europe | | University Hospital, Strasbourg, France | COVID-19 | 04/22 | 06/22 | | |
| Long, Georgina |
| Active, not recruiting | 3 | 423 | Europe, US, RoW | Neoadjuvant ipilimumab + nivolumab, Yervoy + Opdivo, Adjuvant nivolumab, Opdivo | The Netherlands Cancer Institute, Bristol-Myers Squibb | Malignant Melanoma Stage III | 01/24 | 12/28 | | |
ACTRN12613000737730: An open label, single centre, phase II pilot study of neoadjuvant dabrafenib + trametinib in patients with resectable AJCC Stage IIIB-C BRAF V600 mutation positive melanoma |
|
|
| Active, not recruiting | 2 | 35 | | | Melanoma Institute Australia, GlaxoSmithKline Australia | Melanoma | | | | |
ACTRN12614001315606: A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases (ABC - Anti-PD1 Brain Collaboration Study) |
|
|
| Active, not recruiting | 2 | 75 | | | Melanoma Institute Australia , Melanoma Institute Australia | Melanoma Brain Metastases, Melanoma | | | | |
Neo Combi, NCT01972347: Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma |
|
|
| Active, not recruiting | 2 | 35 | RoW | Dabrafenib, GSK2118436, Trametinib, GSK1120212 | Melanoma Institute Australia | Melanoma | 05/17 | 05/24 | | |
|
| Active, not recruiting | 2 | 76 | RoW | Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016 | Melanoma Institute Australia, Melanoma and Skin Cancer Trials Limited, Bristol-Myers Squibb | Melanoma, Brain Metastases | 09/17 | 12/28 | | |
NeoTrio, NCT02858921: Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Dabrafenib, Tafinlar, Trametinib, Mekinist, Pembrolizumab, Keytruda | Melanoma Institute Australia, Merck Sharp & Dohme LLC, Novartis | Melanoma | 01/22 | 11/24 | | |
Neo PeLe, NCT04207086: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma |
|
|
| Active, not recruiting | 2 | 21 | RoW | Pembrolizumab, Keytruda, Lenvatinib, Lenvima | Melanoma Institute Australia, Merck Sharp & Dohme LLC | Melanoma Stage III | 01/23 | 01/33 | | |
| Recruiting | 2 | 20 | RoW | Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination, Opdualag | Melanoma Institute Australia, Bristol-Myers Squibb | Merkel Cell Carcinoma | 04/26 | 04/34 | | |
| Terminated | 2 | 205 | Europe, US, RoW | ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda | Seagen Inc., Merck Sharp & Dohme LLC | Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma | 11/23 | 11/23 | | |
NCT03340129: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) |
|
|
| Recruiting | 2 | 218 | Europe, RoW | Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy | Melanoma Institute Australia, Bristol-Myers Squibb | Melanoma Stage Iv | 08/24 | 08/25 | | |
Neo ReNi II, NCT05418972: A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma |
|
|
| Recruiting | 2 | 20 | RoW | Relatlimab and nivolumab fixed dose combination (FDC), Opdualag | Melanoma Institute Australia, Bristol-Myers Squibb | Stage II Melanoma | 12/24 | 12/34 | | |
KEYNOTE-D36, NCT05309421: A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma |
|
|
| Recruiting | 2 | 90 | RoW | EVX-01, Pembrolizumab 25 MG/ML, Keytruda | Evaxion Biotech A/S, Merck Sharp & Dohme LLC | Melanoma Stage III, Melanoma Stage IV | 06/25 | 07/25 | | |
KEYNOTE-E40, NCT05280314: Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors |
|
|
| Recruiting | 2 | 60 | Europe, US, RoW | IO102-IO103, Pembrolizumab KEYTRUDA® | IO Biotech, Theradex, Almac, Merck Sharp & Dohme LLC | Melanoma, Squamous Cell Carcinoma of Head and Neck | 04/25 | 01/27 | | |
I-MAT, NCT04291885: Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma |
|
|
| Recruiting | 2 | 132 | RoW | Avelumab, anti-PD-L1, Bavencio, Placebo | Melanoma and Skin Cancer Trials Limited | Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Merkel Cell Carcinoma, Stage III, Neuroendocrine Tumors, Carcinoma Neuroendocrine Skin | 04/27 | 04/28 | | |
| Withdrawn | 2 | 44 | RoW | Pembrolizumab, Keytruda, Lenvatinib, Lenvima | Melanoma Institute Australia, Merck Sharp & Dohme LLC | Mucosal Melanoma | 05/26 | 05/36 | | |
| Recruiting | 2 | 1000 | RoW | Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study | Melanoma Institute Australia, Novartis | Melanoma | 07/27 | 12/28 | | |
NCT04834973: A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma |
|
|
| Terminated | 1/2 | 3 | RoW | tigilanol tiglate, EBC-46, pembrolizumab, Keytruda | QBiotics Group Limited, Merck Sharp & Dohme LLC | Melanoma | 07/22 | 07/22 | | |
| Guitera, Pascale |
ACTRN12615000266561: A randomised controlled multicentre trial of imiquimod versus radiotherapy for lentigo maligna (LM) when staged surgical excision with 5mm margins is not possible, is refused, or fails. |
|
|
| Active, not recruiting | 3 | 266 | | | Melanoma and Skin Cancer (MASC) Trials, Cancer Australia | Lentigo maligna (LM) | | | | |
| Completed | 3 | 126 | RoW | Imiquimod, Aldara, Radiotherapy | Melanoma and Skin Cancer Trials Limited, Melanoma Institute Australia | Lentigo Maligna | 12/21 | 03/23 | | |
SONIB, NCT03534947: A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma |
|
|
| Recruiting | 2 | 20 | RoW | Sonidegib, LDE225, Odomzo, Imiquimod, Aldara, Surgery, Excision of remnant invasive basal cell carcinoma, Best supportive care | Melanoma Institute Australia | Basal Cell Carcinoma, Basal Cell Carcinoma of Skin, Site Unspecified, Skin Cancer, Invasive Carcinoma | 06/24 | 06/24 | | |
IMAGE, NCT04385732: Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients |
|
|
| Active, not recruiting | N/A | 670 | RoW | 2D or 3D Melanoma Surveillance Photography | Melanoma and Skin Cancer Trials Limited, Monash University, University of Sydney, The University of Queensland | Melanoma, Skin Cancer, Anxiety and Fear | 02/25 | 02/25 | | |
| Menzies, Alex |
| Recruiting | 2 | 1000 | RoW | Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study | Melanoma Institute Australia, Novartis | Melanoma | 07/27 | 12/28 | | |
| Menzies, Alexander |
ACTRN12616001187437: Molecular Profiling and Matched Targeted Therapy for Patients with Metastatic Melanoma (MatchMel) |
|
|
| Not yet recruiting | 2 | 1000 | | | Melanoma Institute Australia, Melanoma Institute Australia, National Health and Medical Research Council | Metastatic Melanoma | | | | |
NCT03340129: Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) |
|
|
| Recruiting | 2 | 218 | Europe, RoW | Ipilimumab, Yervoy, Nivolumab, Opdivo, Stereotactic Radiotherapy, Salvage therapy | Melanoma Institute Australia, Bristol-Myers Squibb | Melanoma Stage Iv | 08/24 | 08/25 | | |
BELLA, NCT04739670: Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer |
|
|
| Recruiting | 2 | 31 | RoW | Atezolizumab, Bevacizumab, Gemcitabine, Carboplatin | Peter MacCallum Cancer Centre, Australia | Metastatic Triple Negative Breast Cancer | 09/25 | 09/25 | | |
| Osorio, Monica |
ACTRN12614001315606: A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases (ABC - Anti-PD1 Brain Collaboration Study) |
|
|
| Active, not recruiting | 2 | 75 | | | Melanoma Institute Australia , Melanoma Institute Australia | Melanoma Brain Metastases, Melanoma | | | | |
| Recruiting | 2 | 20 | RoW | Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination, Opdualag | Melanoma Institute Australia, Bristol-Myers Squibb | Merkel Cell Carcinoma | 04/26 | 04/34 | | |
Neo ReNi II, NCT05418972: A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma |
|
|
| Recruiting | 2 | 20 | RoW | Relatlimab and nivolumab fixed dose combination (FDC), Opdualag | Melanoma Institute Australia, Bristol-Myers Squibb | Stage II Melanoma | 12/24 | 12/34 | | |
| Recruiting | 2 | 1000 | RoW | Standard therapy or clinical trial, Immunotherapy, Biological agent, Matched targeted therapy, ALK - Ceritinib, BRAF fusion - Trametinib, CCND1 - Ribociclib + Trametinib, CDK4/6 - Ribociclib + Trametinib, CDKN2A - Ribociclib + Trametinib, GNA11 - Trametinib, GNAQ - Trametinib, HRAS - Trametinib, KIT - Pazopanib, KRAS - Trametinib, MAP2K1 - Trametinib, NF1 - Trametinib, MET - Ceritinib, RAS - Ribociclib + Trametinib, ROS1 - Ceritinib, Trametinib and / or supportive care, Trametinib, Supportive care, CDK4/6 and MEK inhibitor, Ribociclib + Trametinib, Compassionate Access Targeted Therapy, Off label use of a matched targeted therapy currently unavailable to the study | Melanoma Institute Australia, Novartis | Melanoma | 07/27 | 12/28 | | |
| Saw, A/Prof Robyn |
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma |
|
|
| Recruiting | 3 | 2998 | Europe, Canada, US, RoW | Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin | Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre | Cutaneous Melanoma, Stage II | 12/29 | 12/34 | | |
QB46C-H04, NCT05234437: A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma |
|
|
| Terminated | 2b | 1 | RoW | tigilanol tiglate, EBC-46 | QBiotics Group Limited | Melanoma | 07/22 | 07/22 | | |
IMAGE, NCT04385732: Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients |
|
|
| Active, not recruiting | N/A | 670 | RoW | 2D or 3D Melanoma Surveillance Photography | Melanoma and Skin Cancer Trials Limited, Monash University, University of Sydney, The University of Queensland | Melanoma, Skin Cancer, Anxiety and Fear | 02/25 | 02/25 | | |
| Silva, Ines |
| Recruiting | 2 | 20 | RoW | Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination, Opdualag | Melanoma Institute Australia, Bristol-Myers Squibb | Merkel Cell Carcinoma | 04/26 | 04/34 | | |
| Not yet recruiting | 2 | 20 | NA | Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination, Opdualag | Melanoma Institute Australia, Bristol-Myers Squibb | Cutaneous Squamous Cell Carcinoma | 09/26 | 07/36 | | |
NCT05102214: HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 150 | RoW | HLX301 | Shanghai Henlius Biotech | Locally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer | 09/23 | 02/24 | | |
| Italiano, Antonie |
NCT05920408: Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours |
|
|
| Terminated | 1b/2a | 6 | Europe | EXS21546 | Exscientia AI Limited, Biotrial | Advanced Solid Tumours | 09/23 | 10/23 | | |
NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
| Dalton, Jo |
IMAGE, NCT04385732: Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients |
|
|
| Active, not recruiting | N/A | 670 | RoW | 2D or 3D Melanoma Surveillance Photography | Melanoma and Skin Cancer Trials Limited, Monash University, University of Sydney, The University of Queensland | Melanoma, Skin Cancer, Anxiety and Fear | 02/25 | 02/25 | | |
| Kitada, Tasuku A |
STX-001-01, NCT06249048: Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab |
|
|
| Recruiting | 1/2 | 108 | US, RoW | STX-001, Keytruda®, Pembrolizumab | Strand Therapeutics Inc. | Advanced Solid Tumor | 05/27 | 11/28 | | |
